Natera, Inc. (NASDAQ:NTRA) Holdings Trimmed by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,344,610 shares of the medical research company's stock after selling 40,380 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 1.73% of Natera worth $331,551,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of NTRA. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Norges Bank purchased a new stake in shares of Natera in the fourth quarter valued at about $224,040,000. Vanguard Group Inc. grew its holdings in shares of Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after purchasing an additional 879,463 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 6,980 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer owned 185,182 shares in the company, valued at $27,795,818.20. This represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total value of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at approximately $20,922,509.35. The trade was a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,272 shares of company stock worth $8,345,368 in the last 90 days. 7.60% of the stock is owned by company insiders.

Natera Stock Performance

NTRA stock traded down $4.14 during trading on Friday, hitting $139.24. The stock had a trading volume of 875,691 shares, compared to its average volume of 1,420,511. The stock has a market cap of $19.01 billion, a price-to-earnings ratio of -94.96 and a beta of 1.73. The company's 50 day moving average price is $160.33 and its two-hundred day moving average price is $158.16. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's revenue was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.56) EPS. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. UBS Group upped their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Piper Sandler upped their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Barclays upped their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.